Essential Clinical Trial Resources for Foreign Pharma Sponsors in China
China has become one of the world’s most important clinical trial destinations, driven by a large and treatment-naive patient population, streamlined regulatory pathways, and a rapidly modernizing clinical research infrastructure. For foreign pharmaceutical sponsors, navigating China’s clinical trial ecosystem requires familiarity with a distinct set of regulatory databases, trial registration systems, contract research organizations (CROs), site networks, and ethical approval processes. This resource guide provides a comprehensive overview of the essential tools and resources that foreign sponsors need to successfully plan, initiate, and execute clinical trials in China.
1. Regulatory Framework for Clinical Trials in China
1.1 CDE Clinical Trial Application (CTA) System
The Center for Drug Evaluation (CDE) operates the centralized clinical trial application system. All interventional clinical trials involving drugs must receive CTA approval from the CDE before initiating. Key resources include:
- CDE Online Application Platform: Electronic submission portal for IND/CTA applications, including protocol, investigator’s brochure, and CMC data packages
- 60-Day Silent Approval Rule: Since December 2018, the CDE has 60 working days to raise objections after CTA submission. If no objection is raised within 60 days, the trial is deemed approved — a significant acceleration from the previous 12–18 month approval timeline.
- CTA Amendment and Notification System: Portal for submitting protocol amendments, safety updates, and annual progress reports
1.2 Ethics Committee (EC) Approval System
Clinical trials in China require dual approval: CDE regulatory approval and ethics committee approval. Key aspects include:
- Lead EC System: Since 2020, multi-center trials can use a single lead EC review (the ethics committee of the leading site) with subsequent site-specific ECs conducting streamlined reviews, reducing total EC approval time from 3–6 months to 30–60 days.
- Clinical Trial Agreement (CTA) and Insurance Requirements: All sponsors must provide clinical trial insurance coverage, and the trial agreement must comply with China’s specific liability and indemnification regulations.
- Informed Consent Standards: China-specific informed consent requirements include mandatory written consent, special provisions for genetic sample collection, and data privacy disclosures aligned with China’s Personal Information Protection Law (PIPL, effective 2021).
2. Clinical Trial Registration and Disclosure Platforms
2.1 Drug Clinical Trial Registration and Information Disclosure Platform (药物临床试验登记与信息公示平台)
URL: www.chinadrugtrials.org.cn
This is China’s primary clinical trial registry, operated by the CDE. It is the functional equivalent of ClinicalTrials.gov for China. Key features include:
- Mandatory Registration: All drug clinical trials conducted in China must be registered within 1 month of receiving CTA approval
- Searchable Database: Over 30,000 registered trials searchable by drug name, indication, sponsor, phase, and site location
- Results Disclosure: Trial results must be posted within 12 months of trial completion for marketed drugs
- Cross-Reference with ClinicalTrials.gov: Many multi-national trials maintain dual registration — sponsors should ensure CDE registration records align with ClinicalTrials.gov entries
2.2 Chinese Clinical Trial Register (ChiCTR)
URL: www.chictr.org.cn
Operated by the Chinese Clinical Trial Registry (a WHO Primary Registry), ChiCTR primarily covers device trials, traditional Chinese medicine studies, and observational research. While drug trials are now registered on the CDE platform, ChiCTR remains valuable for:
- Real-world evidence (RWE) studies and post-marketing observational studies
- Medical device clinical trials
- Traditional Chinese medicine combination therapy studies
- Academic-initiated investigator-sponsor trials (ISTs)
3. Clinical Trial Site Networks and Investigator Databases
3.1 CDE-Qualified Clinical Trial Institutions
The CDE maintains a list of accredited clinical trial institutions (临床试验机构) that have undergone certification and periodic inspection. As of 2026, over 1,100 hospitals have drug clinical trial qualifications, including approximately 400 capable of conducting Phase I / bioequivalence studies. Key tiers include:
| Tier | Institution Examples | Typical Capabilities |
|---|---|---|
| Tier 1 — National Centers | Peking Union Medical College Hospital, Chinese PLA General Hospital (301), Ruijin Hospital (Shanghai), Zhongshan Hospital (Shanghai), West China Hospital (Chengdu) | Phase I–IV, First-in-human, Complex oncology, Rare disease trials; Extensive MRCT experience; Dedicated Phase I units with 30–60 beds |
| Tier 2 — Regional Specialist Centers | Cancer Hospital CAMS (Beijing), Fudan University Shanghai Cancer Center, Guangdong Provincial People’s Hospital, Nanjing Drum Tower Hospital | Phase II–III, Therapeutic area specialists (oncology, cardiology, neurology); Strong patient recruitment networks |
| Tier 3 — Provincial Centers | Provincial-level hospitals in secondary cities (Hangzhou, Wuhan, Chengdu, Zhengzhou, Xi’an) | Phase III–IV, Large patient pools, Lower per-patient costs; Emerging site infrastructure investment |
| Tier 4 — Emerging Sites | Newly qualified hospitals in Tier 2/3 cities | Phase III–IV, Patient recruitment for common diseases; Lower site overhead but variable experience |
3.2 Clinical Research Center Networks
Several organized clinical research networks operate in China:
- China Clinical Research Network (CCRN): Multiple government-supported clinical research platforms focused on specific therapeutic areas (oncology, cardiovascular, metabolic diseases)
- China National Clinical Research Centers (NCRC): 50+ national-level clinical research centers designated by the National Health Commission, each specializing in a specific disease area
- IQVIA, Syneos, and Parexel Site Networks: Global CROs with preferred-site partnerships across 50–150 hospitals in China, offering pre-qualified sites with established quality systems and rapid contract negotiation
4. Contract Research Organizations (CROs) in China
4.1 Global CROs with Strong China Presence
- IQVIA China: The largest global CRO in China with over 5,000 employees, covering all therapeutic areas and offering full-service clinical development, regulatory affairs, and market access consulting
- Parexel China: Strong in oncology, rare disease, and vaccine trials; operates 4 clinical pharmacology units in China
- Syneos Health China: Integrated clinical and commercial solutions with particular depth in CNS and cardiovascular trials
- Labcorp (formerly Covance) China: Central laboratory services combined with clinical trial management, especially strong in bioanalytical services
4.2 Chinese Domestic CROs
- WuXi AppTec (药明康德): China’s largest CRO/CDMO with integrated laboratory, clinical, and manufacturing services. Their clinical CRO division, WuXi Clinical, manages over 200 ongoing trials including 80+ MRCTs.
- Tigermed (泰格医药): The largest pure-play clinical CRO in China, with over 3,000 employees and extensive oncology, vaccine, and device trial experience. Particularly strong in investigator relationships at Tier 1–2 hospitals.
- Beijing Joincare (康龙化成): Vertically integrated CRO/CDMO with growing clinical trial management capabilities and strong chemistry/CMC expertise
- DMed Biopharma (缔脉): Specialized in clinical development services for innovative biotech, with particular expertise in China-U.S. dual-filing strategies
- Huiheng Medical (惠恒医疗): Rapidly growing CRO focused on early-phase oncology trials, with dedicated Phase I units and strong connections to cancer hospitals
5. Genetic Data Management and Biobank Resources
5.1 Human Genetic Resource Administration (HGR)
Foreign sponsors must comply with China’s Human Genetic Resource (HGR) regulations, administered by the Ministry of Science and Technology (MOST). The HGR regime has undergone significant reforms since 2023:
- Online Application System: The MOST HGR platform (https://hgr.most.gov.cn) accepts applications for collection, storage, and outbound transfer of human genetic resources
- Streamlined Approval (2024 Reform): Clinical trials without outbound genetic data transfer can proceed with simplified notification rather than full approval, reducing approval time from 6 months to 30 days
- Data Localization Requirements: Genetic data generated from Chinese clinical trial participants must be stored on servers within mainland China. Foreign sponsors must engage a local data custodian.
- International Sharing Protocol: If data sharing with the global development team is required, sponsors must file an HGR outbound transfer application with a detailed data management plan and ethical justification
5.2 Central Laboratory and Biobank Resources
- Labcorp China (Shanghai): Full-service central laboratory with CAP/ISO 15189 accreditation, supporting hematology, chemistry, pharmacogenomics, and biomarker analysis
- Q2 Solutions China (Shanghai): IQVIA-QualTek JV central lab with specialized immunoassay and genomics capabilities
- WuXi Diagnosis (Shanghai): Comprehensive central lab and biobank services with integrated clinical data management
- KingMed Diagnostics (金域医学): Largest independent clinical lab network in China with 38 laboratories nationwide, offering decentralized lab services for multi-regional trials
6. Patient Recruitment and Retention Resources
6.1 Patient Recruitment Platforms
Digital patient recruitment is increasingly important in China’s clinical trial landscape:
- Clinical Trial Patient Recruitment Platforms: Online portals like Love in Trial (临床试验爱), Baidu Health Clinical Trial Channel, and WeDoctor Clinical Trials connect patients with clinical trial opportunities
- Social Media and Patient Communities: WeChat groups and patient advocacy organizations (e.g., Shanghai Pulmonary Cancer Patient Alliance, China Rare Disease Center) are critical channels for patient awareness and referral
- Doctor Referral Networks: Given China’s hospital-centric healthcare system, site investigator referrals remain the most effective recruitment channel. CRO relationships with department heads are essential.
6.2 Patient Retention Strategies
- Travel Reimbursement and Patient Stipends: Chinese regulations permit patient travel reimbursement and modest compensation for trial participation, which significantly improves retention in multi-city trials
- Remote Monitoring and Decentralized Trial Elements: Since the CDE’s 2023 guidance on decentralized trial elements, sponsors can incorporate remote patient monitoring, local lab sample collection, and telemedicine follow-up visits — tools that have been shown to improve retention by 25–35% in Chinese trials
- Cultural Considerations: Family decision-making is common in Chinese healthcare. Providing family education materials and including family members in the informed consent process has been shown to reduce dropout rates in oncology trials.
7. Practical Steps for Initiating a Clinical Trial in China
- Conduct a China Feasibility Assessment: Evaluate the competitive landscape, available patient populations, site investigator expertise, and regulatory pathway for your specific drug and indication
- Select a CRO Partner: Choose between a global CRO with China infrastructure or a domestic Chinese CRO based on trial complexity, therapeutic area, and budget. Consider a dual-CRO model for first trials in China.
- Submit Pre-IND Meeting Request to CDE: Discuss clinical trial design, bridging study requirements, ethnic sensitivity, and the overall China development plan in a Type B meeting
- Submit CTA with Complete Dossier: Prepare a comprehensive CTA package including protocol, investigator’s brochure, CMC data for the China-market formulation, and informed consent forms in Chinese
- Initiate Ethics Review and Site Contracts: Concurrently with CDE review, begin lead EC submission and site feasibility evaluations at 3–5 prospective trial sites
- Register Trial on CDE Platform: Within 30 days of CTA approval, register the trial on the CDE clinical trial registry
- File HGR Notification/Application: Submit most Chinese HGR records for clinical trials without international data transfer through the simplified notification portal
- Site Initiation and Patient Enrollment: Following CDE approval, EC approval, and HGR clearance, proceed with site initiation visits and begin patient screening
8. Key Regulations and Policy References
| Regulation / Guideline | Year | Impact on Clinical Trials |
|---|---|---|
| Drug Administration Law (2019 Revision) | 2019 | Established 60-day silent approval for CTA; simplified EC approval for multi-site trials; expanded conditional approval pathways |
| Clinical Trial Management Specifications (2020) | 2020 | GCP compliance requirements; investigator qualifications; trial monitoring and auditing standards |
| Human Genetic Resource Management Regulations | 2019 (rev. 2023) | Framework for collection, storage, and international transfer of Chinese genetic data |
| CDE Guidance on Multi-Regional Clinical Trials (MRCT) | 2021 | Design requirements for MRCT including China enrollment targets and subgroup analysis plans |
| CDE Guidance on Decentralized Trial Elements | 2023 | Framework for remote monitoring, telemedicine follow-up, and decentralized trial components |
| ICH E6 (R3) GCP Guideline Implementation | 2024 | Updated GCP standards aligned with international norms |
| China Personal Information Protection Law (PIPL) | 2021 | Patient data privacy, consent standards, and cross-border data transfer restrictions |
Key Takeaway: China’s clinical trial ecosystem has matured enormously over the past five years. With streamlined CTA timelines, a growing network of GCP-certified trial sites, experienced domestic CROs, and a massive patient population, China now offers one of the fastest clinical trial initiation timelines among major pharmaceutical markets — often 3–4 months from CTA submission to first patient enrolled versus 6–10 months in the US or EU. Foreign sponsors that invest in the right partnerships and regulatory preparation can achieve significant speed advantages in their global clinical development programs.
Practical Tip: When selecting trial sites in China, look beyond Tier 1 hospitals in Beijing and Shanghai. Many Tier 2 cities (Nanjing, Hangzhou, Wuhan, Chengdu, Zhengzhou) have excellent GCP-qualified hospitals with large, treatment-naive patient populations, lower site overhead costs, and strong investigator engagement — often resulting in faster patient enrollment and lower per-patient costs than the competitive Tier 1 centers.
